Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 1;8(8):e2528585.
doi: 10.1001/jamanetworkopen.2025.28585.

Access Barriers to Pembrolizumab in Brazil

Pedro Luiz Serrano Uson Junior  1   2 , Uelson Donizeti Rocioli Jr  1 , Maria Fernanda Botelho Teixeira  1 , Isabella Sforzin  1 , Guilherme Andriatte  2 , Francisco Tustumi  1 , Fernando Moura  1 , Mitesh Borad  3 , Flavio Tocci Moreira  2 , Carlos Henrique Sartorato Pedrotti  2
Affiliations

Access Barriers to Pembrolizumab in Brazil

Pedro Luiz Serrano Uson Junior et al. JAMA Netw Open. .
No abstract available

Plain language summary

This cross-sectional study examines the lawsuits that followed national and international policies for pembrolizumab approval.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Borad reported receiving consultant fees from Merck outside the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Pembrolizumab Lawsuits Landscape—Brazilian National NAT-Jus Technical Notes
ANVISA indicates National Health Surveillance Agency from Brazil; CFDA, China Food and Drug Administration; EMA, European Medicines Agency; FDA, US Food and Drugs Administration; ICD-10, International Statistical Classification of Diseases and Related Health Problems, Tenth Revision; PD-L1, programmed death-ligand 1.
Figure 2.
Figure 2.. Quantity of Programmed Death-Ligand 1 (PD-L1) Evaluation Across Multiple Tumors
This figure illustrates the number of cases that evaluated PD-L1 in each tumor; and the levels of PD-L1 according to each case in pembrolizumab lawsuits.
See this image and copyright information in PMC

References

    1. Keytruda pembrolizumabe. MSD. Accessed February 3, 2025. https://saude.msd.com.br/wp-content/uploads/sites/91/2022/12/keytruda_bu...
    1. Na lista do SUS desde novembro de 2020, remédios contra câncer ainda não são fornecidos. CNN Brasil. Accessed February 3, 2025. https://www.cnnbrasil.com.br/saude/na-lista-do-sus-desde-novembro-de-202...
    1. Painel. Saude em numeros 2023. ANAHP. Accessed March 16, 2025. https://www.anahp.com.br/wp-content/uploads/2023/05/Painel-Anahp_2023.pdf
    1. Boing AC, de Andrade FB, Bertoldi AD, et al. Prevalências e desigualdades no acesso aos medicamentos por usuários do Sistema Único de Saúde no Brasil em 2013 e 2019. Cad Saúde Pública. 2022;38(6):e00114721. doi: 10.1590/0102-311XPT114721 - DOI - PubMed
    1. Sumula Vinculante n.61 do STF. Jusbrasil. Accessed March 18, 2025. https://www.jusbrasil.com.br/jurisprudencia/stf/sumulas/sumula-vinculant...